Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 25 versus HY PAM 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 25 versus HY PAM 25.
ALDORIL 25 vs HY-PAM "25"
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.
None Documented
None Documented
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Terminal elimination half-life 6-8 hours in healthy adults; prolonged to 12-18 hours in renal impairment (CrCl <30 mL/min) and in elderly patients.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Primarily renal (60-70% unchanged drug), with 30-40% biliary/fecal elimination as metabolites.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination